Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, postmarketing, prospective study analysing Baseline Seizure Related Disability Assessment Scale (SERDAS) Scores in an Observational Study of Brivaracetam

Next Previous
Trial Profile

A multicentre, postmarketing, prospective study analysing Baseline Seizure Related Disability Assessment Scale (SERDAS) Scores in an Observational Study of Brivaracetam

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Adverse reactions
  • Sponsors UCB Pharma Inc

Most Recent Events

  • 18 Apr 2024 Interim Results(At data snapshot (06/03/2022), n=252) Evaluating effectiveness of adjunctive brivaracetam, presented at the 76th Annual Meeting of the American Academy of Neurology 2024
  • 27 Apr 2023 Results of a post-hoc analysis performed sub-groups seizure free (SF) and not SF (nSF) during 6-month retrospective baseline, and patients who were or were not more than or equal to 6 months SF at any time during BRV treatment presented at the 75th Annual Meeting of the American Academy of Neurology 2023
  • 27 Apr 2023 Pooled analysis of data from two studies (Europe: EP0077/NCT02687711; United States: EP0088), presented at the 75th Annual Meeting of the American Academy of Neurology 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top